

What Is Claimed Is:

1. A method for treating a B-cell malignancy, comprising the step of administering to a subject having a B-cell related malignancy a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-CD19 antibody.

2. The method of claim 1, wherein said therapeutic composition comprises a combination of at least one naked anti-CD19 antibody and an anti-CD20 antibody.

3. The method of claim 2, wherein said anti-CD20 antibody is a naked anti-CD20 antibody.

4. The method of claim 2, wherein said therapeutic composition comprises a fusion protein of said combination of antibodies.

5. The method of claim 1, wherein said therapeutic composition additionally comprises a cytokine.

6. A method for treating a B-cell malignancy, comprising the step of administering to a subject having a B-cell malignancy a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-CD22 antibody, administered parenterally in a dosage of from 20 to 1500 mg per dose.

7. The method of claim 6, wherein said anti-CD22 antibody is parenterally administered in a dosage of 20 to 500 milligrams protein per dose.

8. The method of claim 6, wherein said radiolabeled immunoconjugate comprises a radionuclide selected from the group consisting of  $^{198}\text{Au}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{90}\text{Y}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{87}\text{Cu}$ ,  $^{211}\text{At}$ ,  $^{213}\text{Bi}$  and  $^{222}\text{Ac}$ .

9. The method of claim 6, wherein said radiolabeled anti-CD22 immunoconjugate further comprises a cytokine moiety, wherein said cytokine moiety is selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$  and GM-CSF.

10. The method of claim 6, wherein said therapeutic composition comprises a combination of at least one naked anti-CD22 antibody and an anti-CD19 antibody, a combination of at least one naked anti-CD22 antibody and an anti-CD20 antibody, or a combination of at least one naked anti-CD22 antibody, an anti-CD19 antibody and an anti-CD20 antibody.

11. The method of claim 10, wherein said therapeutic composition comprises a fusion protein of said combination of antibodies.

12. The method of claim 6, wherein said anti-CD22 antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, and humanized antibody.

13. The method of claim 12, wherein said anti-CD22 antibody is the LL2 antibody.

14. The method of claim 6, wherein said therapeutic composition comprises at least two monoclonal antibodies that bind with distinct CD22 epitopes, wherein said CD22 epitopes are selected from the group consisting of epitope A, epitope B, epitope C, epitope D and epitope E.

15. The method of claim 6, wherein said B-cell malignancy is selected from the group consisting of indolent forms of B-cell lymphomas, aggressive forms of B-cell lymphomas, chronic lymphatic leukemias, and acute lymphatic leukemias.

16. The method of claim 15, wherein said B-cell lymphoma is a non-Hodgkin's lymphoma.

17. The method of claim 6, further comprising the step of administering a therapeutic protein or chemotherapeutic treatment, wherein said therapeutic protein is selected from the group consisting of antibody, immunoconjugate, antibody-immunomodulator fusion protein and antibody-toxin fusion protein.

18. The method of claim 17, wherein said therapeutic protein or said chemotherapeutic treatment is administered prior to the administration of said anti-CD22 antibody.

19. The method of claim 17, wherein said therapeutic protein or said chemotherapeutic treatment is administered concurrently with the administration of said anti-CD22 antibody.

20. The method of claim 17, wherein said therapeutic protein or said chemotherapeutic treatment is administered after the administration of said anti-CD22 antibody.

21. The method of claim 17, wherein said chemotherapeutic treatment consists of the administration of at least one drug selected from the group consisting of cyclophosphamide, etoposide, vincristine, procarbazine, prednisone, carmustine, doxorubicin, methotrexate, bleomycin, dexamethasone, phenyl butyrate, brostatin-1 and leucovorin.

22. The method of claim 11, wherein said therapeutic composition comprises a tetravalent construct comprising anti-CD22 antibodies

23. The method of claim 11, wherein said therapeutic composition comprises a multi-specific construct of anti-CD20, anti-CD22 and anti-CD19 antibodies.